F110. SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING

BACKGROUND: Symptomatic remission (SR) is an important outcome for schizophrenia patients [1]. In pivotal trials, paliperidone 3-monthly formulation (PP3M) demonstrated favorable efficacy and tolerability in schizophrenia, including achievement of SR [2–4]. However, due to the selective nature of ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Schizophr Bull
Main Authors: Garcia-Portilla, M P, Llorca, P M, Maina, G, Bozikas, V P, Devrimci-Ozguven, H, Kim, S W, Bergmans, P, Usankova, I, Cherubin, P, Najarian, Dean, Pungor, K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Poster Session II
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6455476/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbz018.522
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados